Product Description
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: COVID-19|Communicable Diseases|Parkinson's Disease|Respiratory Tract Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RTB101-211 | P2 |
Active, not recruiting |
COVID-19 |
2021-02-01 |
25% |
| ACTRN12619000372189 | P2 |
Recruiting |
Parkinson's Disease |
2019-11-29 |
|
| RTB-BEZ235-202 | P2 |
Active, not recruiting |
Respiratory Tract Infections|Communicable Diseases |
2018-05-03 |